New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients

Kohrt, Holbrook E; Olshen, Richard A; Bermas, Honnie R; Goodson, William H; Wood, Douglas J; Henry, Solomon; Rouse, Robert V; Bailey, Lisa; Philben, Vicki J; Dirbas, Frederick M; Dunn, Jocelyn J; Johnson, Denise L; Wapnir, Irene L; Carlson, Robert W; Stockdale, Frank E; Hansen, Nora M; Jeffrey, Stefanie S

doi:10.1186/1471-2407-8-66

Table 1 Characteristics of NSLN- and NSLN+ cases among SLN+ patients (Bay Area SLN Database).

From: New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients

	Tumor-free NSLN				Tumor-involved NSLN				Univariate P ∫	Multivariate P ∫∫	%NSLN+ (NSLN+/SLN+)	TOTAL SLN+
Patient and Tumor Characteristics	Number of Pts (n = 184)	%	Mean	SEM*	Number of Pts (n = 101)	%	Mean	SEM*				Number of Pts (n = 285)	%
Patient Age (years)			55.8	0.89			53	1.14	0.084	NA
Tumor Type
Infiltrating Ductal Carcinoma	159	86			87	86			0.781	NA	35%	246	86.3
Invasive Lobular Carcinoma	18	10			9	9					33%	27	9.5
Mixed Carcinoma	6	3			5	5					45%	11	3.9
Tubular Carcinoma	1	1			0	0					0%	1	0.4
Tumor size (cm)			2.11	0.1			2.97	0.18	<0.001	<0.001
Tumor size (AJCC)									0.001	0.045
T1	117	64			39	39					25%	156	54.7
T1a (mic)	1	1			0	0					0%	1	0.4
T1a	6	3			2	2					25%	8	2.8
T1b	19	10			3	3					14%	22	7.7
T1c	91	49			34	34					27%	125	43.9
T2	59	32			50	50					46%	109	38.2
T3	8	4			12	12					60%	20	7.0
Tumor grade†									0.001	0.736
G1: Nottingham combined histologic score 3–5	68	37			23	23					25%	91	31.9
G2: Nottingham combined histologic score 6–7	81	44			39	39					33%	120	42.1
G3: Nottingham combined histologic score 8–9	35	19			39	39					53%	74	26.0
ER status									0.004	0.079
Negative	17	9			21	21					55%	38	13.3
Positive	134	73			60	59					31%	194	68.1
Unknown	33	18			20	20					38%	53	18.6
PR status									0.015	0.869
Negative	35	19			31	31					47%	66	23.2
Positive	116	63			50	50					30%	166	58.2
Unknown	33	18			20	20					38%	53	18.6
HER2/neu expression									0.256	NA
Not overexpressed, 0+ or 1+	81	44			38	38					32%	119	41.8
Equivocal, weak overexpression, 2+	2	1			2	2					50%	4	1.4
Overexpressed, 3+	29	16			23	23					44%	52	18.2
Unknown	72	39			38	38					35%	110	38.6
Angiolymphatic invasion									<0.001	<0.001
None	95	52			23	23					19%	118	41.4
Present	25	14			70	69					74%	95	33.3
Unknown	64	35			8	8					11%	72	25.3
*Sentinel Lymph Node Characteristics*
No. SLNs Removed			1.96	0.07			1.87	0.09	0.511	NA
= 1	71	39			42	42			0.806		37%	113	39.6
= 2	67	36			37	37					36%	104	36.5
>2	46	25			22	22					32%	68	23.9
No. SLNs Tumor-involved			1.33	0.05			1.39	0.07	0.426	NA
= 1	137	73			71	70			0.679		34%	208	73.0
= 2	38	21			23	23					38%	61	21.4
>2	9	6			7	7					44%	16	5.6
Size of SLN metastases§									<0.001	<0.001
Isolated tumor cells or clusters ≤ 0.2 mm	61	33			3	3					4.7%	64	22.5
Micrometastases, >0.2 mm to 2 mm	117	64			83	82					42%	200	70.2
Macrometastases, >2 mm	6	3			15	15					71%	21	7.4
Sentinel lymph node metastases identification									<0.001	NA
Hematoxylin and eosin staining	122	61			98	97					45%	220	77.2
Immunohistochemistry	62	34			3	3					4.6%	65	22.8

∫ Univariate analyses calculated by χ 2 test and Wilcoxon rank sum test.
∫∫ Multivariate analyses calculated by logistic regression of significant factors by univariate analysis.
*SEM, standard error of the mean.
†Determined according to modified Scarff-Bloom-Richardson grading system.
§Determined according to AJCC criteria, 6th ed.
NA, variable not included in multivariate analysis (not an independent factor or not significant in univariate analysis)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us